Pfizer's targeted lung cancer drug Xalkori got a thumbs down from the U.K.'s cost-effectiveness gatekeepers. But in its announcement of draft guidance, the National Institute for Health and Clinical Excellence seemed ready to change its mind--if the price was right.
In the annals of Big Pharma, 2012 was expected to be the year of all patent-cliff years, with more than a dozen patent expirations. The biggest blockbuster lost patent protection in 2011--Pfizer's Lipitor--but in 2012, a whole list of big sellers would drop. Even the Lipitor damage would hit then, because its patent expired only one month before 2011 ended.
Sanofi's rifampin-and-isoniazid combination capsule, Rifamate, hit the shortage list last week.
The logistics of getting drugs delivered in underdeveloped countries can be tricky. Many companies turn to partners with the expertise that can help them navigate the import laws and distribution obstacles that those countries present.
Should taxpayers enjoy lower drug prices if federal money backed development? At least one U.S. senator thinks so, now that Pfizer has slapped a $2,000-per-month sticker price on the new rheumatoid arthritis drug Xeljanz.
The fight over drug patents in India is quickly ratcheting up even as other countries are looking at new twists on the model for getting their hands on cheaper drugs.
Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
Mytrus has found a new patron as the startup advances mobile apps for clinical trials. InVentiv Health, a contract research organization (CRO) for pharma and device companies, has snapped up an equity stake in Mytrus and plans to partner on commercializing the startup's mobile apps.
Last year was a tough one for Pfizer ($PFE), having to shoulder a full 12 months without the riches of Lipitor to rely on. Still, CEO Ian Read did the best he could with what he had to work with. And for that, he got a small raise, although nothing like the 44% upgrade he received a year ago.
Lipitor as a loss leader? That's the approach Wegmans' pharmacies are taking. As the Philadelphia Inquirer reports, the grocery store chain offers generic versions of Lipitor for free, as a way to bring in new pharmacy customers. And the promotion must be successful--Wegmans just extended it through the end of this year.